Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials

被引:0
作者
Timothy Arthur Chandos Snow
Naveed Saleem
Gareth Ambler
Eleni Nastouli
Mervyn Singer
Nishkantha Arulkumaran
机构
[1] University College London,Bloomsbury Institute of Intensive Care Medicine
[2] University College London,Department of Statistical Science
[3] University College London Hospital,Department of Clinical Virology
[4] UCL Great Ormond Street Institute of Child Health,Department of Infection, Immunity and Inflammation
来源
Intensive Care Medicine | 2021年 / 47卷
关键词
COVID-19; Immunologic factors; Interleukin-6; Meta-analysis;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:641 / 652
页数:11
相关论文
共 542 条
[1]  
Wu Z(2020)Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72314 cases from the Chinese center for disease control and prevention JAMA 323 1239-1242
[2]  
McGoogan JM(2020)Variation in US Hospital mortality rates for patients admitted with COVID-19 during the first 6 months of the pandemic JAMA Intern Med 384 693-704
[3]  
Asch DA(2020)Long term outcomes of critically ill COVID-19 pneumonia patients: early learning Intensive Care Med 202 1460-1462
[4]  
Sheils NE(2021)Dexamethasone in hospitalized patients with Covid-19 N Engl J Med 2 e594-e602
[5]  
Islam MN(2020)Immunomodulators in COVID-19: two sides to every coin Am J Respir Crit Care Med 202 812-821
[6]  
Chen Y(2020)COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study Lancet Rheumatol 8 1233-1244
[7]  
Werner RM(2020)Characterization of the inflammatory response to severe COVID-19 illness Am J Respir Crit Care Med 339 b2700-926
[8]  
Buresh J(2020)Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes Lancet Respir Med 366 l4898-3457
[9]  
Doshi JA(2009)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration BMJ 336 924-468
[10]  
McCue C(2019)RoB 2: a revised tool for assessing risk of bias in randomised trials BMJ 25 3443-40